TrialBone marrow transplantation2016

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial).

P Montesinos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.